Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL4159977 | 0.87 | KDM4E (0.35) | KDM4EBRD4RXFP1KEAP1NFE2L2 | |
| Butyric Acid SCHEMBL4153572 | 0.85 | KDM4E (0.33) | KDM4EBRD4TP53RXFP1KEAP1 | |
| Butyric Acid SCHEMBL4155439 | 0.85 | KDM4E (0.33) | KDM4EBRD4TP53RXFP1KEAP1 | |
| Butyric Acid SCHEMBL4155243 | 0.85 | KDM4E (0.39) | KDM4ETP53RXFP1SLC6A2SLC6A4 | |
| Butyric Acid SCHEMBL4160306 | 0.85 | RXFP1 (0.36) | KDM4EBRD4TP53RXFP1 | |
| Butyric Acid SCHEMBL4155236 | 0.83 | MAPT (0.36) | KDM4ETP53RXFP1SLC6A2SLC6A4 | |
| SCHEMBL4166441 | 0.83 | KDM4E (0.32) | KDM4ETP53 | |
| Butyric Acid SCHEMBL4166269 | 0.82 | KDM4E (0.37) | KDM4ETP53RXFP1KEAP1NFE2L2 | |
| Butyric Acid SCHEMBL4155430 | 0.82 | KDM4E (0.37) | KDM4ETP53RXFP1KEAP1NFE2L2 | |
| SCHEMBL3255165 | 0.82 | KDM4E (0.35) | KDM4ETP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | KDM4E 1970/4885BRD4 545/4885TP53 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.